HSCS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
HSCS is not a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock is trading below its pivot and under bearish moving averages, with no strong proprietary buy signal, no recent news catalyst, neutral hedge fund and insider activity, and weak latest-quarter fundamentals. If the user is impatient and wants a direct entry, this is still not an attractive buy today.
The current pre-market price is 1.9504, sitting below the pivot level of 2.054 and just under S1 at 1.966, which suggests the stock is still दबाव under nearby resistance. The moving averages are bearish, with SMA_200 > SMA_20 > SMA_5, confirming the broader trend remains weak. MACD histogram is slightly positive at 0.011 but is contracting, so momentum is fading rather than accelerating upward. RSI_6 at 29.579 is near oversold territory but not yet a strong reversal signal. Overall, the technical setup is weak with only a mild short-term bounce possibility.
The only mild positive is the technical mean-reversion setup from the low RSI and the modeled stock trend suggesting possible modest upside over the next day, week, and month. Gross margin remained relatively healthy at 59.06, which shows the business can still generate efficient gross profit when revenue exists.
No news in the recent week means there is no event-driven catalyst to re-rate the stock. Hedge funds are neutral and insiders are neutral, so there is no sign of conviction buying. AI Stock Picker shows no signal today and SwingMax also has no recent signal. The latest quarter showed revenue at 0, net income down to -1,985,208, and EPS falling to -0.63, indicating continued financial weakness. Congress trading data is unavailable, and there is no valuation support provided.
In 2026/Q3, HeartSciences reported revenue of 0, which is flat year over year but reflects no top-line growth. Net income worsened to -1,985,208, down 21.73% YoY, and EPS declined to -0.63, down 75.49% YoY. Gross margin was 59.06, which is solid, but the overall quarter remains weak because the company is still unprofitable and not generating revenue growth.
No analyst rating or price target data was provided, so there is no visible Wall Street upgrade/downgrade trend to support the stock. Based on the available data, Wall Street pros would likely see the main positives as the gross margin and possible short-term technical bounce, while the main cons are lack of revenue, negative earnings, bearish trend structure, and no recent catalyst.
